ParkinsonFranceV1, Main, Exploration, bibRecordById, pubmed:2096108

Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians

Identifieur interne : 005135 ( Main/Exploration ); précédent : 005134; suivant : 005136

Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians

Auteurs : D. Milon [France] ; H. Allain ; J. M. Reymann ; G. Morel ; O. Sabouraud ; J. Van Den Driessche

Source :

Fundamental and clinical pharmacology [ 0767-3981 ] ; 1990.

RBID : Pascal:91-0171486

Descripteurs français

Pascal (Inist)
- Heptaminol, Cardiotonique, Vasodilatateur coronarien, Voie parentérale, Homme, Parkinson maladie, Système nerveux pathologie, Toxicité, Bromocriptine, Antiparkinsonien, Hypotension artérielle, Hémodynamique, Appareil circulatoire pathologie, Chimiothérapie, Traitement, Stimulant dopaminergique, Récepteur dopaminergique D2, Renin.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Arterial hypotension, Blood Pressure (drug effects), Bromocriptine (adverse effects), Bromocryptine, Cardiotonic agent, Cardiovascular disease, Chemotherapy, Coronary vasodilator agent, D2 Dopamine receptor, Dopamine agonist, Double-Blind Method, Female, Heart Rate (drug effects), Hemodynamics, Heptaminol (adverse effects), Heptaminol (therapeutic use), Human, Humans, Hypotension, Orthostatic (chemically induced), Hypotension, Orthostatic (drug therapy), Injections, Intravenous, Male, Middle Aged, Nervous system diseases, Parenteral administration, Parkinson Disease (drug therapy), Parkinson disease, Renin, Renin (blood), Toxicity, Treatment.
MESH :
- chemical , adverse effects : Bromocriptine, Heptaminol.
- chemical , blood : Renin.
- chemically induced : Hypotension, Orthostatic.
- drug effects : Blood Pressure, Heart Rate.
- drug therapy : Hypotension, Orthostatic, Parkinson Disease.
- chemical , therapeutic use : Heptaminol.
- Double-Blind Method, Female, Humans, Injections, Intravenous, Male, Middle Aged.

Abstract

Nineteen patients were included in the study: 7 displayed spontaneous orthostatic hypotension (OH), and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D." last="Milon">D. Milon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHR Rennes, lab. pharmacologie exp. clin.</s1>
<s2>35043</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J. M." last="Reymann">J. M. Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G." last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O." last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J." last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0171486</idno>
<date when="1990">1990</date>
<idno type="stanalyst">PASCAL 91-0171486 INIST</idno>
<idno type="RBID">Pascal:91-0171486</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C03</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001448</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A51</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001A51</idno>
<idno type="wicri:doubleKey">0767-3981:1990:Milon D:randomized:double:blind</idno>
<idno type="wicri:Area/Main/Merge">005C16</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:2096108</idno>
<idno type="wicri:Area/PubMed/Corpus">001827</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001827</idno>
<idno type="wicri:Area/PubMed/Curation">001786</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001786</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001786</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001786</idno>
<idno type="wicri:Area/Ncbi/Merge">000C38</idno>
<idno type="wicri:Area/Ncbi/Curation">000C38</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C38</idno>
<idno type="wicri:doubleKey">0767-3981:1990:Milon D:randomized:double:blind</idno>
<idno type="wicri:Area/Main/Merge">005A77</idno>
<idno type="wicri:Area/Main/Curation">005135</idno>
<idno type="wicri:Area/Main/Exploration">005135</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D." last="Milon">D. Milon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHR Rennes, lab. pharmacologie exp. clin.</s1>
<s2>35043</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J. M." last="Reymann">J. M. Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G." last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O." last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J." last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</analytic>
<series><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
<imprint><date when="1990">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Arterial hypotension</term>
<term>Blood Pressure (drug effects)</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocryptine</term>
<term>Cardiotonic agent</term>
<term>Cardiovascular disease</term>
<term>Chemotherapy</term>
<term>Coronary vasodilator agent</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Heart Rate (drug effects)</term>
<term>Hemodynamics</term>
<term>Heptaminol (adverse effects)</term>
<term>Heptaminol (therapeutic use)</term>
<term>Human</term>
<term>Humans</term>
<term>Hypotension, Orthostatic (chemically induced)</term>
<term>Hypotension, Orthostatic (drug therapy)</term>
<term>Injections, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parenteral administration</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Renin</term>
<term>Renin (blood)</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
<term>Heptaminol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Renin</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypotension, Orthostatic</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term>
<term>Heart Rate</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypotension, Orthostatic</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Heptaminol</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Heptaminol</term>
<term>Cardiotonique</term>
<term>Vasodilatateur coronarien</term>
<term>Voie parentérale</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Toxicité</term>
<term>Bromocriptine</term>
<term>Antiparkinsonien</term>
<term>Hypotension artérielle</term>
<term>Hémodynamique</term>
<term>Appareil circulatoire pathologie</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique D2</term>
<term>Renin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nineteen patients were included in the study: 7 displayed spontaneous orthostatic hypotension (OH), and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Région Bretagne</li>
</region>
</list>
<tree><noCountry><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
<name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G." last="Morel">G. Morel</name>
<name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J. M." last="Reymann">J. M. Reymann</name>
<name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O." last="Sabouraud">O. Sabouraud</name>
<name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J." last="Van Den Driessche">J. Van Den Driessche</name>
</noCountry>
<country name="France"><region name="Région Bretagne"><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D." last="Milon">D. Milon</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005135 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005135 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:91-0171486
   |texte=   Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians

Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.